US Patent

US11771686 — Compositions and kits for omeprazole suspension

Method of Use · Assigned to Azurity Pharmaceuticals Inc · Expires 2040-03-01 · 14y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects liquid diluents, formulations, and kits for preparing reconstituted suspensions of omeprazole, a proton pump inhibitor.

USPTO Abstract

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

Drugs covered by this patent

Prilosec (omeprazole) · AstraZeneca (originally Astra AB)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-623`	—	Prilosec

Patent Metadata

Patent number: US11771686
Jurisdiction: US
Classification: Method of Use
Expires: 2040-03-01
Drug substance claim: No
Drug product claim: No
Assignee: Azurity Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.